Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Assessing the role of venetocl...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

Bibliographic Details
Main Authors: Rami S. Komrokji, Avani M. Singh, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew Kuykendall, Jeffrey E. Lancet, David A. Sallman
Format: Article
Language:English
Published: Nature Publishing Group 2022-11-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00744-z
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1038/s41408-022-00744-z

Similar Items

  • <i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
    by: Rami Komrokji, et al.
    Published: (2022-11-01)
  • Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    by: Akriti G. Jain, et al.
    Published: (2024-02-01)
  • Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm
    by: Zhuoer Xie, et al.
    Published: (2025-05-01)
  • P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
    by: Luis E. Aguirre, et al.
    Published: (2023-08-01)
  • A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
    by: Nathan Radakovich, et al.
    Published: (2022-10-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs